Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...

If you’ve been debating starting a weight-loss treatment like tirzepatide or semaglutide, you’re going to want to listen ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly.

A new study is shedding light on which of two drugs currently approved by the U.S. Food and Drug Administration for weight ...

Kara Kennedy's husband was a yo-yo dieter for decades, until he discovered Zepbound – an Ozempic-like drug – and lost 3.5 stone. Then the problem became side affects and how to keep finding the next f ...

Zepbound’s greater weight loss is a huge advantage for Eli Lilly, which is competing with Novo Nordisk for a larger share of ...

Adults who take Zepbound lose more weight than those who take competitor weight loss drug Wegovy, according to new clinical ...

Amid the war on obesity, a clear winner has emerged in a battle between two weight-loss injectables. Zepbound (tirzepatide), ...

President Joe Biden wants Medicare and Medicaid to cover weight-loss drugs, a proposal that would expand access to the costly ...

Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from ...

Leptin by itself doesn't hold promise for weight loss — but a new mouse study suggests it could work in combination with ...

Eli Lilly said its weight loss drug Zepbound led to 47% greater weight reduction than rival medicine Wegovy, made by Novo ...